Benign prostatic hyperplasia/urinary retention:

Indications for: RAPAFLO

Benign prostatic hyperplasia.

Adult Dosage:

Take with food once daily. Normal renal function: 8mg. Renal impairment (CrCl 30–50mL/min): 4mg. Difficulty swallowing pills/caps: may open caps and sprinkle contents on a tablespoonful of applesauce; swallow immediately (within 5mins) without chewing and follow with an 8oz glass of water.

Children Dosage:

Not established.

RAPAFLO Contraindications:

Severe renal impairment (CrCl <30mL/min). Severe hepatic impairment (Child-Pugh score ≥10). Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir).

RAPAFLO Warnings/Precautions:

Not for treating hypertension. Exclude prostate cancer. Anticipated cataract surgery (may cause intraoperative floppy iris syndrome; advise ophthalmologist). Pregnancy, nursing mothers: not indicated for use in females.

RAPAFLO Classification:

Alpha-1 blocker.

RAPAFLO Interactions:

See Contraindications. Concomitant other α-blockers, other strong P-glycoprotein inhibitors (eg, cyclosporine): not recommended. May be potentiated by moderate CYP3A4 inhibitors (eg, erythromycin, diltiazem, verapamil). Caution with other antihypertensives or PDE-5 inhibitors.

Adverse Reactions:

Retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, nasal congestion.

Drug Elimination:

Fecal, renal.

Generic Drug Availability:


How Supplied:

Caps—30, 90